Acrivon Therapeutics Stock (NASDAQ: ACRV)

Acrivon Therapeutics (NASDAQ:ACRV) Stock, Quote.Headers.trade-ideas

Acrivon Therapeutics

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Biotech

Earnings

Earnings Beats

News

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

ACRV

ADPT

ATHA

RAPT

Athira Pharma, Inc (NASDAQ: ATHA) recently announced that it has dosed the last patient in the phase II/III LIFT-AD study, which is evaluating its pipeline candidate, fosgonimeton for the treatment of mild-to-moderate Alzheimer&#39;s disease (AD).

Athira Completes Dosing in Alzheimer&#39;s Study, Stock Up

ALGS

BEAM

Beam Therapeutics Inc. (NASDAQ: BEAM) announced that it has dosed the first patient in the phase I/II study, evaluating its investigational in vivo base editing therapy, BEAM-302, for the treatment of alpha-1 antitrypsin deficiency (AATD).

Beam Therapeutics Begins Dosing in Phase I/II AATD Study

MRNS

NERV

RARE

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), along with partner Mereo BioPharma (MREO), announced new positive 14-month data from the phase II portion of the phase II/III Orbit study evaluating setrusumab (UX143) in patients with osteogenesis imperfecta.

Ultragenyx Posts New Data From Bone Disease Study

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics Inc

On Friday, the market cap of&nbsp;Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) soared <a href="https://www.benzinga.com/news/management/24/11/41856784/elon-musks-wealth-tops-300-billion-as-teslas-market-cap-soars-above-1-trillion">past the $1 trillion mark</a>, a surge attributed to CEO Elon Musk&#8217;s bet on President-elect Donald Trump.
What Happened: Following Trump&#8217;s victory and his comeback as the 47th U.S. president, Tesla&#8217;s stock experienced a sharp rally, propelling Musk&#8217;s fortune past the $300 billion mark.
During an appearance on Yahoo Finance, Wedbush analyst Dan Ives praised Musk&#8217;s support of Trump as a &#8220;poker move for the ages.&#8221; He anticipates an expedited autonomous sector, which could be worth $1 trillion alone for Tesla&#8217;s AI segment.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&quot;Autonomous is going to get fast-tracked in our opinion, and that is significant,&quot; Wedbush managing director <a href="https://twitter.com/DivesTech?ref_src=twsrc%5Etfw">@DivesTech</a> says on <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a>. &quot;That&#39;s worth $1 trillion alone in terms of the AI piece to Tesla, and that&#39;s why for Musk, the bet on Trump, it&#39;s a poker move for the ages.&quot; <a href="https://t.co/U3rMjisDSE">pic.twitter.com/U3rMjisDSE</a>
&mdash; Yahoo Finance (@YahooFinance) <a href="https://twitter.com/YahooFinance/status/1855005452930580789?ref_src=twsrc%5Etfw">November 8, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/personal-finance/24/11/41773588/elon-musks-mom-knew-he-was-a-genius-by-3-years-old-but-worried-hed-end-up-in-a-basement-now-hes-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Mom Knew He Was A &#8216;Genius&#8217; By 3 Years Old But Worried He&#8217;d &#8216;End Up In A Basement&#8217;</a>
In a separate post, Gene Munster, managing partner at Deepwater Asset Management, noted Tesla&#8217;s impressive 44% rally over the past 12 trading days. &#8220;This is more than just a meme stock,&#8221; he wrote on X, formerly Twitter.
Munster believes that Tesla&#8217;s accelerating delivery growth&nbsp;and the long-term opportunity around&nbsp;autonomy will power the fundamentals&nbsp;leading to further price appreciation. &#8220;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> up 44% over the last 12 trading days, compared to the Nasdaq up 4%. This is more than just a meme stock. The accelerating delivery growth next year (flat-ish in 2024 and up +20% in 2025) and the long-term opportunity around autonomy will power the fundamentals that should…
&mdash; Gene Munster (@munster_gene) <a href="https://twitter.com/munster_gene/status/1854912992472649980?ref_src=twsrc%5Etfw">November 8, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Tesla&#8217;s stock surged nearly 29% this week following Trump's victory in the U.S. presidential election, as investors grow hopeful that President-elect&#8217;s return to the White House <a href="https://www.benzinga.com/markets/equities/24/11/41832876/elon-musk-shines-in-trump-sweepstakes-a-big-win-for-tesla-dan-ives-thinks-so">could favor the automaker</a>.
The Tesla CEO was a key political supporter of Trump's 2024 campaign, reportedly donating over $130 million to aid his re-election.
<a href="https://www.benzinga.com/news/24/11/41766547/trump-gives-victory-speech-in-florida-as-winning-pennsylvania-puts-him-at-brink-of-victory-vows-to-f">Trump's victory speech</a> also praised Musk, dedicating nearly four minutes to call him a &#8220;super genius&#8221; and highlighting achievements, including SpaceX launches and its expanding satellite internet network.
Musk has also shown interest in leading a proposed Department of Government Efficiency (DOGE) to reduce federal waste. Trump has suggested Musk for the role of &#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41619022/trumps-billionaire-ally-plans-to-join-elon-musks-doge-if-named-treasury-secretary-recommen">Secretary of Cost-Cutting</a>,&#8221; overseeing efforts to trim $2 trillion in federal spending.
Last month, Tesla reported third-quarter revenue of $25.18 billion, reflecting an 8% year-over-year increase. However, the figure fell short of the Street consensus estimate of $25.37 billion, according to data&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">from Benzinga Pro</a>.
Price Action: Tesla shares closed Friday&#8217;s session with an 8.19% gain, finishing at $321.22. In after-hours trading, the stock rose further, reaching $322.80, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41764063/dogecoin-powers-to-7-month-high-as-investors-anticipate-musk-headed-doge-department-under-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin Powers To 7-Month High As Investors Anticipate Musk-Headed DOGE Department Under Trump</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Tesla

Analyst Color

Equities

Tech

TSLA

As Tesla Market Capitalization Soars Past $1 Trillion, Dan Ives Calls Musk's Trump Bet 'Poker Move For The Ages: Gene Munster Say It Is 'More Than Just A Meme Stock'

TRNR

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

VLCN

FCEL

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) with a Buy and maintains $6 price target.

Price Target

OCGN

Chardan Capital Maintains Buy on Ocugen, Maintains $6 Price Target

Chardan Capital analyst Matthew Barcus maintains Zura Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZURA#NASDAQ">ZURA</a>) with a Buy and lowers the price target from $14 to $12.

ZURA

Chardan Capital Maintains Buy on Zura Bio, Lowers Price Target to $12

Canaccord Genuity analyst Yuri Lynk upgrades Stantec (TSX:<a class="ticker" href="https://www.benzinga.com/stock/STN#TSX">STN</a>) from Hold to Buy and raises the price target from C$125 to C$135.

Upgrades

TSX:STN

Canaccord Genuity Upgrades Stantec to Buy, Raises Price Target to C$135

Wells Fargo analyst Andrew Bauch maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Overweight and raises the price target from $52 to $55.

AFRM

Wells Fargo Maintains Overweight on Affirm Holdings, Raises Price Target to $55

Loop Capital analyst Yun Kim maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Hold and raises the price target from $45 to $55.

Loop Capital Maintains Hold on Dynatrace, Raises Price Target to $55

GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>), SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>), Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) and Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) are the top five trending tickers on Stocktwits Friday. Here&#8217;s a look at what grabbed <a href="https://www.benzinga.com/trading-ideas/24/11/41856335/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-42">retail investors&#8217; attention.</a>
GME GM-Meme: GameStop tops the list this week. The stock moved on heavy volume and zero fundamentals Friday, as the original meme-stock tends to do. Keith Gill, a.k.a. Roaring Kitty, dumped his Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) shares at the <a href="https://www.benzinga.com/news/24/10/41614177/roaring-kitty-puts-chewy-stock-in-the-litter-box-gamestop-shares-move-higher-after-hours">end of October </a>and GameStop has climbed steadily since.&nbsp;
SOFI Surges: SoFi shares have climbed 17%<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41847971/jim-cramer-this-tech-stock-is-a-buy-sofi-technologies-is-good"> this week</a> as investors hope for deregulation under a second Trump presidency. The stock pumped on heavy volume and ended the day more than 9% higher. 
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
TSLA For President: Tesla shares blasted higher after Donald Trump won the presidential election. Tesla CEO Elon Musk joined Trump several times on the campaign trail and may even be appointed to a position in the administration.&nbsp;
Investors may also consider Trump's EV and tariff policy beneficial to Tesla, as both could potentially reduce competition for the U.S.-based EV giant. The stock has been up 30% since Tuesday, and its market cap has <a href="https://www.benzinga.com/news/management/24/11/41856784/elon-musks-wealth-tops-300-billion-as-teslas-market-cap-soars-above-1-trillion">now reached </a>more than $1 trillion. 
SAVA: Cassava Sciences is a frequent flier on the Stocktwits trending list. HC Wainwright &amp; Co. analyst Vernon Bernardino reiterated Cassava Sciences as a Buy and maintained an ambitious price target of $116 on Friday. The stock is currently trading at just under $27. 
AVXL: Anavex Life Sciences rounds out the list as another heavily-shorted biotech stock that moved on heavy volume, despite a lack of news. According to data from Benzinga Pro, 21.78% of shares are being sold short, and the stock saw more than triple its average trading volume on Friday. 
GME, SOFI, TSLA, SAVA, AVXL Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, GameStop shares closed up 6.1% at $24.88, SoFi shares closed up 9.33% at $13.01, Tesla shares closed up 8.19% at $321.22, Cassava Sciences shares closed up 6.55% at $27.00 and Anavex Life Sciences shares ended the day up 21% at $9.24 on Friday.&nbsp;
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image: Shutterstock

Large Cap

Topics

Movers

AVXL

CHWY

SAVA

SOFI

Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla?

Loop Capital analyst Alton Stump upgrades Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) from Hold to Buy and raises the price target from $419 to $559.

Loop Capital Upgrades Domino's Pizza to Buy, Raises Price Target to $559

Jones Trading analyst Jason Weaver maintains GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) with a Buy and raises the price target from $18.75 to $32.

Jones Trading Maintains Buy on GEO Group, Raises Price Target to $32

EF Hutton analyst Jason Kolbert maintains CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Buy and maintains $10 price target.

CTSO

EF Hutton Maintains Buy on CytoSorbents, Maintains $10 Price Target

Telsey Advisory Group analyst Dana Telsey maintains Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) with a Outperform and raises the price target from $19 to $22.

WRBY

Telsey Advisory Group Maintains Outperform on Warby Parker, Raises Price Target to $22

Rosenblatt analyst Kevin Cassidy maintains Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) with a Buy and maintains $17 price target.

OUST

Rosenblatt Maintains Buy on Ouster, Maintains $17 Price Target

Rosenblatt analyst Catharine Trebnick maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Buy and maintains $45 price target.

Rosenblatt Maintains Buy on RingCentral, Maintains $45 Price Target

Rosenblatt analyst Catharine Trebnick maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Buy and raises the price target from $85 to $90.

FTNT

Rosenblatt Maintains Buy on Fortinet, Raises Price Target to $90

Planet 13 Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PLNH#OTC">PLNH</a>) reported Friday afternoon a strong revenue increase of 29.7% year-over-year for Q3 2024, reaching $32.2 million. The growth was fueled by the expansion into the Florida market and solid performance at its Illinois store. 
Despite the revenue boost, the company posted a net loss of $7.4 million; still a significant improvement from the $46.3 million net loss in Q3 2023.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Improved Margins&nbsp;</h3>
The company's gross profit rose to $16.7 million, up from $11.1 million in the same quarter last year. Gross margins also improved, reaching 51.9%, compared to 44.7% previously. Planet 13 attributed the margin growth to enhanced yields from cultivation and higher margin sales in <a href="https://www.benzinga.com/topic/florida-cannabis">Florida</a>.&nbsp;
Operating expenses dropped sharply by 66.4%, thanks to reduced impairment losses, signaling better cost management.
Read Also:<a href="https://www.benzinga.com/general/health-care/24/11/41843261/kentucky-gov-beshear-the-jury-is-no-longer-out-kentuckians-want-medical-cannabis"> Kentucky Gov. Beshear: &#8216;The Jury Is No Longer Out,&#8217; Kentuckians Want Medical Cannabis</a>
<h3 class="wp-block-heading">Adjusted EBITDA And Future Outlook</h3>
Planet 13 reported an adjusted EBITDA of $1.3 million, a substantial increase from $0.2 million in Q3 2023, highlighting improved operating leverage.&nbsp;
In spite of consumer spending challenges, co-CEO Bob Groesbeck<a href="https://www.globenewswire.com/us/news-release/2024/11/08/2977890/0/en/Planet-13-Announces-Q3-2024-Financial-Results.html"> pointed out </a>the strategic focus on cash flow and scaling its footprint.
"Despite Florida not moving forward with adult-use [cannabis legalization], we see a significant growth runway by expanding our store footprint and enhancing cultivation assets in the state. In addition to our<a href="https://www.benzinga.com/topic/florida-cannabis"> Florida operations</a>, we&#8217;re focused on driving growth by scaling our neighborhood store network and broadening the distribution of our HaHa edibles," said Larry Scheffler, co-CEO of Planet 13.
With $27.4 million in cash, up from $11.8 million at the end of 2023, Planet 13 is positioning itself for future growth. The company's expansion in Florida and recent acquisitions signal a commitment to broadening its market presence as it aims for profitability in 2025.
Read Next: <a href="https://www.benzinga.com/news/earnings/24/11/41843751/canopy-growth-q2-net-revenue-drops-9-yoy-projects-positive-earnings-ahead">Canopy Growth: Q2 Net Revenue Drops 9% YoY, Projects Positive Earnings Ahead</a>

Cannabis

Management

PLNH

Planet 13 Slashes Costs 66%: Revenue Grows, Losses Shrink — Is This The Turning Point?

Rosenblatt analyst Catharine Trebnick maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and raises the price target from $45 to $50.

FIVN

Rosenblatt Maintains Buy on Five9, Raises Price Target to $50

Rosenblatt analyst Barton Crockett maintains Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Buy and lowers the price target from $48 to $46.

PINS

Rosenblatt Maintains Buy on Pinterest, Lowers Price Target to $46

Acrivon Therapeutics, Inc. (ACRV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Silvan Tu...

Acrivon Therapeutics, Inc.: Strong Buy on Robust Clinical Data and Strategic Market Positioning

H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on ACRV stock, giving a Buy rating today. Emily Bodnar's rating is based o...

Promising Efficacy and Safety Profile of ACR-368 Bolster Buy Rating for Acrivon Therapeutics

Acrivon Therapeutics, Inc. ( ($ACRV) ) has shared an announcement. Acrivon Therapeutics has shared promising Phase 2 data for ACR-368, showing a 62...

Acrivon Therapeutics: Promising Trial Results and FDA Clearance

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report), wit...

Piper Sandler Keeps Their Buy Rating on Acrivon Therapeutics, Inc. (ACRV)

TD Cowen analyst Marc Frahm maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report) today. The company's shares closed last ...

TD Cowen Remains a Buy on Acrivon Therapeutics, Inc. (ACRV)

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on ACRV stock, giving a Buy rating yesterday. Michael Okunewitch has giv...

Acrivon Therapeutics: Buy Rating Justified by Promising Clinical Data and Strategic Research Initiatives

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

An update from Acrivon Therapeutics, Inc. ( ($ACRV) ) is now available. Acrivon Therapeutics has initiated a Phase 1 clinical trial for ACR-2316, a...

Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline

In a report released today, Silvan Tuerkcan from JMP Securities maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report), wit...

Acrivon Therapeutics: Promising Innovations in WEE1/PKMYT1 Inhibition and AP3 Platform Drive Buy Rating

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report), with a pri...

Acrivon Therapeutics: Buy Rating Driven by Promising Oncology Advancements and Strategic Positioning

Health Care

Press Releases

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316

Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Acrivon Therapeutics

Acrivon Therapeutics (ACRV) Forecast

Acrivon Therapeutics (NASDAQ:ACRV) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga